Today is Rare Disease Day. Read how OMass Therapeutics, is using new technologies to develop treatments for rare immunological and genetic diseases. 🔬 ox.ac.uk/research/resea… @OxSciences Syncona Innovate UK Oxford Chemistry Wolfson College, Oxford #OxfordImpacts #SDG3

Read Syncona CEO Chris Hollowood reflect on the current state of the biotech sector and what's next for Syncona: bit.ly/3J5zORb

#ICYMI the sale of Silicon Valley Bank UK SVB UK is now HSBC Innovation Banking UK to HSBC over the weekend will safeguard thousands of British jobs, at no cost to the taxpayer. Here's how government, the tech and life sciences sectors worked together to deliver the best possible outcome for the UK economy.

Syncona CEO Chris Hollowood has been quoted in today's The Times and The Sunday Times, having spoken to Alex Ralph about the opportunities and challenges facing biotechs in the UK. bit.ly/3MG6J1c #UKbiotech #opportunities

Syncona is pleased to announce that its portfolio company Quell has entered into a collaboration, exclusive option and license agreement with AstraZeneca, in which Quell will receive $85 million upfront from AstraZeneca. Read more here: bit.ly/3P1EQSa

We’re excited to launch a leading ophthalmic gene therapy company Beacon Therapeutics with £96 million Series A financing by combining AGTC’s late-stage X-linked retinitis pigmentosa (XLRP) programme with two proprietary pre-clinical programmes. More here: synconaltd.com/news-and-insig…

Following today’s launch of Beacon Therapeutics, a new leading ophthalmic gene therapy company, please visit our new refreshed website to find out more about the company. Watch the full video on Beacon’s launch here: synconaltd.com/news-and-insig…

This week not only did we launch our new brand but we launched Beacon Therapeutics, a new leading ophthalmic gene therapy company. Watch the full video on Beacon’s launch here: synconaltd.com/news-and-insig… #ophthalmology

Today Syncona announces its Preliminary Results for the 12-month period ending 31 March 2023. Management will be delivering a presentation followed by a Q&A session which begins at 9am. To register for the webcast, and to see the full release, click below: bit.ly/440xXot

Today FreelineLife announced it has dosed its first patient with its novel adeno-associated virus (#AAV) #genetherapy candidate for #Gaucher disease, marking an important step forward for the Gaucher community. Read the full announcement here: synconaltd.com/news-and-insig…

Strategy Director at Syncona portfolio company OMass Therapeutics OMass Therapeutics, Miguel Campos Silva, speaks about OMass’ #sustainability journey and Syncona’s active involvement. Read the full Q&A with Miguel here: synconaltd.com/news-and-insig… #lifescience

“Simply being the first mover against a given target won’t be enough”, Syncona CEO Chris Hollowood shares his perspective on the future of the scientific landscape. Find out more about current opportunities in the blog: synconaltd.com/news-and-insig… #lifescience #pharma #blog

We’ve released our Q1 update, highlighting the continued progress across our maturing portfolio. Our portfolio companies continue to deliver on their clinical and operational plans as our late-stage clinical companies approach important milestones: tinyurl.com/59u7ef3e

Syncona is pleased to announce its Interim Results for the 6-month period ending 30 September 2023. To read the full announcement, please visit the following link: synconaltd.com/investors/resu…

Autolus Therapeutics announced it has submitted its Biologics License Application to the US #FDA for obe-cel for patients with relapsed/refractory adult B-Cell Acute Lymphoblastic #Leukaemia. Read the full announcement here: synconaltd.com/news-and-insig… #biotech #celltherapy

Syncona was pleased to recently welcome two senior leaders to the business in, Executive Partner, John Tsai, and Managing Partner, Roel Bulthuis. Here they discuss their experience, what attracted them to Syncona, and their priorities since joining. synconaltd.com/news-and-insig…

Today Syncona announces its Annual Results for the 12-month period ending 31 March 2024. Management will be delivering a presentation followed by a question and answer session which begins at 9am this morning. To register, and to see the full release: synconaltd.com/investors/resu…

Today we announced our first quarter update, highlighting strong clinical execution from a rebalanced and diversified portfolio that continues to attract significant external capital. Read the full announcement here: londonstockexchange.com/news-article/S…

Today Syncona announced its Half Year Results. Management will be delivering a presentation followed by a Q&A session which begins at 9am this morning. To register for the webcast, and to see the full release, please click the link below: synconaltd.com/investors/resu…

Today Syncona today announced its Third Quarter Update covering the period from 01 October to 31 December 2024. To see the full release, please click here: londonstockexchange.com/news-article/S…